PASSAGE BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
PASSAGE BIO, INC. (PASG) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $5.31 per share for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-09-03.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-09-03
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $5.81, a 6.29% decline year-over-year.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $6.20, a 453.57% increase year-over-year.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $1.12, a 34.94% increase year-over-year.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $0.83, a 75.94% decline year-over-year.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $0.81, a 65.24% decline from fiscal 2022.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $2.33, a 81.73% decline from fiscal 2021.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $12.75, a 10.49% increase from fiscal 2020.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $11.54, a 253.99% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.31 S-4/A · filed 2026-09-03 | |||||||
| 2026-03-31 | $5.81 S-4 · filed 2026-07-21 | |||||||
| 2025-12-31 | $6.07 S-4/A · filed 2026-09-03 | |||||||
| 2025-09-30 | $6.02 10-Q · filed 2025-11-10 | |||||||
| 2025-06-30 | $6.02 S-4/A · filed 2026-09-03 | |||||||
| 2025-03-31 | $6.20 S-4 · filed 2026-07-21 | $0.31 10-Q · filed 2025-05-13 | ||||||
| 2024-12-31 | $20.20 S-4/A · filed 2026-09-03 | $1.01 10-K · filed 2025-03-04 | ||||||
| 2024-09-30 | $20.60 10-Q · filed 2025-11-10 | $1.03 10-Q · filed 2024-11-13 | ||||||
| 2024-06-30 | $21.60 10-Q · filed 2025-08-12 | $1.08 10-Q · filed 2024-08-08 | ||||||
| 2024-03-31 | $1.12 10-Q · filed 2025-05-13 | |||||||
| 2023-12-31 | $0.81 10-K · filed 2025-03-04 | |||||||
| 2023-09-30 | $0.82 10-Q · filed 2024-11-13 | |||||||
| 2023-06-30 | $0.83 10-Q · filed 2024-08-08 | |||||||
| 2023-03-31 | $0.83 10-Q · filed 2024-05-14 | |||||||
| 2022-12-31 | $2.33 10-K · filed 2024-03-04 | |||||||
| 2022-09-30 | $2.52 10-Q · filed 2023-11-13 | |||||||
| 2022-06-30 | $2.59 10-Q · filed 2023-08-07 | |||||||
| 2022-03-31 | $3.45 10-Q · filed 2023-05-11 | |||||||
| 2021-12-31 | $12.75 10-K · filed 2023-03-06 | |||||||
| 2021-09-30 | $13.64 10-Q · filed 2022-11-10 | |||||||
| 2021-06-30 | $15.64 10-Q · filed 2022-08-04 | |||||||
| 2021-03-31 | $17.18 10-Q · filed 2022-05-16 | |||||||
| 2020-12-31 | $11.54 10-K · filed 2022-03-03 | |||||||
| 2020-09-30 | $11.27 10-Q · filed 2021-11-04 | |||||||
| 2020-06-30 | $11.09 10-Q · filed 2021-08-05 | |||||||
| 2020-03-31 | $9.93 10-Q · filed 2021-05-05 | |||||||
| 2019-12-31 | $3.26 10-K · filed 2021-03-03 | |||||||
| 2019-09-30 | $0.76 10-Q · filed 2020-11-10 | |||||||
| 2019-06-30 | $0.76 10-Q · filed 2020-08-13 | |||||||
| 2019-03-31 | $0.73 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |